Skip to main content

Table 1 Baseline characteristics

From: Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China

Characteristics

IPE 4 g/day (n = 125)

IPE 2 g/day (n = 124)

Placebo (n = 124)

Total (n = 373)

Age, mean ± SD (years)

48.5 ± 10.58

48.8 ± 10.44

49.3 ± 10.13

48.9 ± 10.36

Age ≤ 65 years, n (%)

118 (94.4%)

113 (91.1%)

116 (93.5%)

347 (93.0%)

Men, n (%)

93 (74.4%)

93 (75.0%)

94 (75.8%)

280 (75.1%)

Nationality, China (%)

125 (100.0%)

123 (99.2%)

124 (100.0%)

372 (99.7%)

Han ethnicity, n (%)

114 (91.2%)

116 (93.5%)

116 (93.5%)

346 (92.8%)

Height, mean ± SD (cm)

169.0 ± 7.76

169.1 ± 7.49

169.8 ± 7.26

169.3 ± 7.49

Weight, mean ± SD (kg)

76.5 ± 11.66

75.3 ± 11.91

78.4 ± 13.49

76.7 ± 12.41

Body mass index, mean ± SD (kg/m2)

26.7 ± 2.75

26.2 ± 3.03

27.1 ± 3.30

26.6 ± 3.05

Body mass index < 25, n (%)

33 (26.4%)

47 (37.9%)

33 (26.6%)

113 (30.3%)

Statin use

13 (10.4%)

13 (10.5%)

13 (10.5%)

39 (10.5%)

Baseline median TG (mmol/L)

9.470

9.215

9.270

9.370

Baseline TG > 8.5 mmol/L

67 (53.6%)

68 (54.8%)

67 (54.0%)

202 (54.2%)

Baseline median LDL-C (mmol/L)

1.420

1.290

1.360

1.360

Diabetes mellitus

23 (18.4%)

28 (22.6%)

26 (21.0%)

77 (20.6%)

Hypertension

56 (44.8%)

64 (51.6%)

60 (48.4%)

180 (48.3%)

  1. All data were collected from the randomized population
  2. Abbreviations: TG triglyceride, LDL-C low-density lipoprotein-cholesterol, SD standard deviation